This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Haemonetics price target raised to $93 from $90 at Barrington
Barrington raised the firm’s price target on Haemonetics (HAE) to $93 from $90 and keeps an Outperform rating on the shares after the company announced that it had acquired Vivasure Medical Limited, an Ireland-based developer of advanced polymer implants and delivery systems. The firm is increasing its price target based on a positive view of the Vivasure transaction, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
